133 results about "Epirubicin" patented technology

The invention discloses a method for preparing folic acid coupled acetyl pullulan polysaccharide and the nanoparticles thereof, a preparation of drug-loaded nanoparticles which take the compound as the carrier and the role of the drug-loaded nanoparticles on the tumor cells. Firstly, the water soluble pullulan polysaccharide is converted to hydrophobic polymers by acetylation, so as to be conductive to the preparation of the nanoparticles and the loading of a hydrophobic drug, and the tumor cells with the high expression of the folate receptor can be targeted after the coupling of the folic acid by esterification. The drug-loaded nanoparticles are prepared by taking epirubicin as a model drug and adopting the solvent dispersion method, and the role of the drug-loaded nanoparticles on the tumor cells are evaluated by the in vitro cell uptake test. The results show that the method for preparing the folic acid-acetyl pullulan polysaccharide nanoparticles by the solvent dispersion method is simple, the reproducibility is good, the expanded production is easy, the drug-loading ratio is high, and the drug-loaded nanoparticles can be taken into the tumor cells by the route of the folate receptor.

The invention discloses a medicinal composition for treating non-small cell lung cancer. The medicinal composition comprises a target medicament, a chemotherapeutic medicament and a traditional Chinese medicament, wherein the target medicament is one or more of bortezomib, imatinib, gefitinib and sunitinib; the chemotherapeutic medicament is one or more of 5-fluorouracil, carboplatin, epirubicin, adriamycin and fludarabine; and the traditional Chinese medicament is one or more of salvia miltiorrhiza, astragalus membranaceus, sappanwood, Chinese pulsatilla root and portulaca oleracea. The medicinal composition has a remarkable synergetic treatment effect when being used for treating the non-small cell lung cancer, and can be used for remarkably strengthening the cancer-inhibition effect compared with treatment of a single medicament, so that the medicament dosage can be reduced, and the toxic and side effects of chemotherapeutic medicaments can be reduced.

The invention discloses an epirubicin loaded graphene quantum dot drug carrying system and a preparation method thereof. The preparation method includes the following steps: preparation of graphene quantum dots by a hydrothermal method; loading an anti-cancer drug with the graphene quantum dots; and performing a drug slow-release experiment, and performing a cytotoxicity test on the drug carrying system. The graphene quantum dots prepared by the hydrothermal method are used as a drug carrier for being loaded with epirubicin, greatly improve the drug loading rate, and show a quite good inhibitory effect on tumor HeLa cells. The preparation method of the drug carrying system is simple to operate, mild in reaction conditions and high in drug loading rate, and is expected to have a broad application prospect in the field of biological medicine.

The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and/or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. 3, 4, and/or 5. Gene expression profiles for evaluating multidrug resistance for ER positive and ER negative breast cancers are also provided.

The invention belongs to the medicine technical field, relates to epirubicin hydrochloride liposome and a preparation method. The liposome comprises epirubicin hydrochloride and neutral phospholipid and cholesterol and/or negative charge phospholipids and/or long-circulating phospholipids and buffer solution, and actively carries drug with a PH gradient method or an ammonium sulphate gradient method; the entrapment rate of the achieved liposome is more than 90%, to make smaller volume contain more main drug component of epirubicin. Compared with the exiting techniques, the epirubicin hydrochloride liposome and the preparation method has the advantages of high drug content, high bioavailability, long internal circulation time, low toxic and side effect and other advantages; besides, the production cost can be reduced obviously, the epirubicin hydrochloride liposome is more suitable for industrial production after being made into lyophilized preparation. The liposome is clinically suitable for the tumor therapy, in particular to the tumor therapy for children.

The invention relates to a preparation method for an intermediate 4'-epidaunorubicin hydrochloride of epirubicin hydrochloride. The preparation method comprises the steps of trifluoroacetyl protection, oxidation, reduction, hydrolyzation, etc. The method effectively inhibit generation of (methylthio)methyl ether, increases selectivity for sodium borohydride during the reduction process and is mild in reaction conditions. The total yield of the reaction is over 40% (based on epidaunorubicin hydrochloride) and the purity reaches 99.5%.

The invention relates to a preparation method for a Sappan Wood extract, in particular to a preparation process for Sappan Wood extract perfusate and application thereof in treating bladder cancer, which solves the problem of the application of the Sappan Wood extract in treating bladder cancer tumors. The preparation process comprises the following steps: taking and smashing Sappan Wood, carrying out water extracting for three times, combining the extracting solutions obtained by three-time water extracting, and carrying out decompression concentrating; standing overnight, and removing sediments; adding petroleum ether, extracting, and retaining aqueous phase; adding ethyl acetate, extracting, and removing the aqueous phase; carrying out decompression volatilizing to remove all the ethyl acetate; weighing dry substances, adding purified water to enable the dry substance content to be 2%, heating for dissolving, standing overnight at room temperature, and filtering out sediments; and freeze-drying, and carrying out split charging. The experiment research result shows that the extract has obvious killing effect on bladder neoplasm cells; and compared with mitomycin, epirubicin, Pirarubicin and other anticancer drugs, which are clinically and frequently used, the Sappan Wood extract perfusate has the advantages of high anticancer activity, less toxicity, safety, effectiveness and the like.

The invention relates to non-spherical drug-loaded particles and a controlled release preparation of a lactyl polymer and preparation methods thereof. The non-spherical particles of polylactic-co-glycolic acid (PLGA) are prepared by using an emulsion-solvent volatilization method assisted by small molecule materials. The PLGA is used as raw material coated with at least one of the following hydrophobic drugs: all-trans retinoic acid, paclitaxel, epirubicin, camptothecin or roxithromycin, wherein the mass ratio of the hydrophobic drug to a lactyl polymer high polymer material is 1:4-40. The drug-loaded particles of the all-trans retinoic acid are prepared and subjected to in vitro drug release evaluation. The results show that the preparation method has the advantages of simple preparation process, good reproducibility, significantly increased drug loading amount and encapsulation efficiency relative to spherical particles, very good controlled-release effect, no hemolysis initiation and safety use. The novel carrier and preparation have a potential industrial production value in the field of long-circulating controlled release of the hydrophobic drugs.

The invention provides a novel intermediate and a novel route for synthesizing epirubicin hydrochloride by utilizing the intermediate. The route is simple, cheap and efficient, achieves better energy conservation and emission reduction, and avoids the problems that an intermediate generated by the existing epirubicin hydrochloride synthesis route is water-instable and easy to decompose and a yield of the whole route is low. The route uses a low-cost and easy-to-obtain reagent and adopts a removable selective protection means; generated impurities are few; the purity is high; a yield is high.

The present invention relates to the field of pharmaceutical technology, and is especially epirubicin liposome and its preparation process. The epirubicin liposome of the present invention consists of epirubicin, phosphatide, cholesterol, sodium deoxycholate, etc.; has stable quality and less toxic side effect; and is suitable for clinical application.

The invention provides a pseudomonas engineering bacteria for producing an epirubicin. The preparation method of the pseudomonas engineering bacteria comprises the following steps: eliminating dnrH gene, dnrX gene and dnrU gene in an adriamycin biosynthesis gene cluster from streptomyces peucetius ATCC 29050; permuting dnmV gene to be aveBIV gene from an abamectin biosynthesis gene cluster; inserting a Pm promoter from pseudomonas before coding doxA gene of oxidation-reduction enzyme; and integrating the modified gene cluster and the screening marker gene into the genome of the pseudomonas putida KT2440 to obtain the pseudomonas engineering bacteria. The pseudomonas engineering bacteria lays a foundation for the heterologous expression and the large-scale industrial production of the epirubicin, thereby being wide in application value.

The invention provides a novel intermediate and a novel route for synthesizing epirubicin hydrochloride by utilizing the intermediate. The route is simple, cheap and efficient, achieves better energy conservation and emission reduction, and avoids the problems that an intermediate generated by the existing epirubicin hydrochloride synthesis route is water-instable and easy to decompose and a yield of the whole route is low. The route uses a low-cost and easy-to-obtain reagent and adopts a removable selective protection means; generated impurities are few; the purity is high; a yield is high.

The invention discloses a novel method for synthesizing epirubicin hydrochloride (compound 1) from adriamycin. Epirubicin is directly obtained by selective oxidation and reduction. Compared with the existing method, the novel method has the advantages that the reaction route is more concise, the synthesis efficiency is improved, raw materials for reaction are easily obtained, conditions are mild, the energy consumption and the cost are reduced, and the total yield reaches 68 percent.

The invention discloses a method for treating bladder cancer through promoting pharmorubicin by a bacillus calmette guerin vaccine (BCG), and specifically relates to the field of combined treatment ofthe bladder cancer in clinical medicine. The method comprises a method for researching synergism of the BCG to the pharmorubicin in a cellular level and a method for synergism of the in-vivo BCG to the pharmorubicin. According to the invention, through using the method for researching the synergism of the BCG to the pharmorubicin in the cellular level and the method for the synergism of the in-vivo BCG to the pharmorubicin, a combined medication scheme is provided to improve treatment efficiency and reduce toxic and side effects during drug perfusion. The method disclosed by the invention isnot high in prefused drug concentration, but long in intra-bladder retention time, thereby being better in the anti-tumor effect without generating an adverse reaction.

The invention relates to the technical field of biological medicine, in particular to a chemotherapy pharmaceutical composition and application thereof. The invention relates to a chemotherapy pharmaceutical composition, which comprises cepharanthine and epirubicin. Before epirubicin is administrated, cepharanthine is administrated firstly, and the cancer cell inhibiting effect of epirubicin can be synergistically enhanced. According to the scheme, the technical problems that the curative effect of epirubicin is limited, and adverse reactions and drug resistance are easily generated when a cancer patient uses epirubicin for a long time are solved. The composition can be applied to clinical practices of treatment of various cancers, reduces adverse reactions of epirubicin, and prevents drugresistance of epirubicin at the same time.

A crystalline form of epirubicin hydrochloride, named herein as “type II” crystalline epirubicin hydrochloride, has excellent thermal stability. Type II crystalline epirubicin hydrochloride has a powder X-ray diffraction pattern having average values of diffraction angle (2θ) and relative intensity P(%) as presented in the following table:

The invention belongs to the technical field of pharmaceutical preparations, and provides epirubicin hydrochloride lyophilized injectable powder and a preparation method of the epirubicin hydrochloride lyophilized injectable powder. According to the preparation method, mannitol is adopted and used as a propping agent during preparing the epirubicin hydrochloride lyophilized injectable powder, the pH (Potential of Hydrogen) of the liquid medicine is adjusted to 4.5 to 6.0 by hydrochloric acid or sodium hydroxide solution, and therefore, the hydrolyzing of the main medicine is inhibited, and the stability of the main medicine is improved; the pre-freezing temperature is controlled to below -40 DEG C, and the sublimation temperature in lyophilization is controlled to -15 DEG C, and as a result, the stability of the medicine can be improved. The prepared epirubicin hydrochloride lyophilized injectable powder is stable, and can prevent the human body from damage due to the anaphylaxis of lactose in an original preparation and preservative methylparaben, thus the safety of the epirubicin hydrochloride lyophilized injectable powder can be improved.

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.